Dr. Thomas Boat Named Executive Associate Dean at UC College of Medicine
Boat will be responsible for operational oversight and strategic planning of all activities within the
Im delighted that Tom has accepted my invitation to join the leadership team, said David Stern, MD, dean of the college and vice president for health affairs at the UC Academic Health Center. Toms extraordinary experience with the clinical operations at Cincinnati Childrens and the
Boat stepped down in April 2007 after 14 years as chair of the UC department of pediatrics and director of the Cincinnati Children's Research Foundation. He remains on staff at Cincinnati Children's
Im eager to work with colleagues in the clinical departments at the
A pediatric pulmonologist by training, Boat worked early in his career to define the pathophysiology of airway dysfunction and develop more effective therapies for chronic lung diseases of childhood, such as cystic fibrosis.
Boat joined Cincinnati Children's in 1993, after serving as chairman of pediatrics at the
Boat is a member of the
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.